GUILFORD, Connecticut, and TOKYO, Japan, December 9, 2020 — InveniAI® LLC, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, and Kyowa Kirin Co., Ltd. (Kyowa Kirin), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, are pleased to announce they have expanded their collaboration agreement to harness the power of InveniAI's AI-platform, AlphaMeld®, for novel target discovery.
Expansion of existing collaboration will leverage InveniAI® technology to identify, evaluate, and optimize novel targets for Kyowa Kirin's antibody technology. Kyowa Kirin will select multiple programs to advance into clinical development, and InveniAI® is eligible to receive an upfront payment, development and commercial milestones, and royalties.
InveniAI and Kyowa Kirin have been collaborating since 2018. Through this expansion, Kyowa Kirin will leverage AlphaMeld® for novel target discovery and validation to generate a clinical pipeline of therapeutic antibodies that address the enduring unmet needs of patients across multiple diseases.
"As we work towards our mission to contribute to human health and well-being worldwide through state-of-the-art therapeutic modalities, we are excited to advance the next generation of antibody technology which offers numerous advantages over traditional monoclonal antibodies," said Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Head of R&D Division of Kyowa Kirin.
"After a successful initial collaboration, our expanded partnership with Kyowa Kirin evidences the continued success of our AI-powered technology to drive the discovery and development of meaningful therapeutics across multiple modalities such as antibody, small molecule, RNAi, and gene therapy," said Krishnan Nandabalan, Ph.D., President and CEO, InveniAI LLC. "One of the earliest programs, BXCL501, developed by our sister company, has recently completed a Phase III readout making this the first AI-powered platform to accomplish this feat."